

# Decision Analysis in SHared decision making for Thromboprophylaxis during Pregnancy (DASH-TOP): a sequential explanatory mixed methods pilot study protocol

Brittany Humphries,<sup>1</sup> Montserrat León-García,<sup>2,3</sup> Shannon Bates,<sup>4</sup> Gordon Guyatt,<sup>1,4</sup> Mark Eckman,<sup>5</sup> Rohan D'Souza,<sup>6,7,8</sup> Nadine Shehata,<sup>9</sup> Susan Jack,<sup>1,10</sup> Pablo Alonso-Coello,<sup>2,11</sup> Feng Xie  <sup>1,12</sup>

**To cite:** Humphries B, León-García M, Bates S, et al. Decision Analysis in SHared decision making for Thromboprophylaxis during Pregnancy (DASH-TOP): a sequential explanatory mixed methods pilot study protocol. *BMJ Open* 2021;11:e046021. doi:10.1136/bmjopen-2020-046021

► Prepublication history and additional material for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-046021>).

Received 18 October 2020

Revised 21 December 2020

Accepted 11 March 2021

## ABSTRACT

**Introduction** Decision analysis is a quantitative approach to decision making that could bridge the gap between decisions based solely on evidence and the unique values and preferences of individual patients, a feature especially important when existing evidence cannot support clear recommendations and there is a close balance between harms and benefits for the treatments options under consideration. Low molecular weight heparin (LMWH) for the prevention of venous thromboembolism (VTE) during pregnancy represents one such situation. The objective of this paper is to describe the rationale and methodology of a pilot study that will explore the application of decision analysis to a shared decision-making process involving prophylactic LMWH for pregnant women or those considering pregnancy who have experienced a VTE.

**Methods and analysis** We will conduct an international, mixed methods, explanatory, sequential study, including quantitative data collection and analysis followed by qualitative data collection and analysis. In step I, we will ask women who are pregnant or considering pregnancy and have experienced VTE to participate in a shared decision-making intervention for prophylactic LMWH. The intervention consists of three components: a direct choice exercise, a values elicitation exercise and a personalised decision analysis. After administration of the intervention, we will ask women to make a treatment decision and measure decisional conflict, self-efficacy and satisfaction. In step II, which follows the analysis of quantitative data, we will use the results to inform the qualitative interview. Step III will be a qualitative descriptive study that explores participants' experiences and perceptions of the intervention. In step IV, we will integrate findings from the qualitative and quantitative analyses to obtain meta-inferences.

**Ethics and dissemination** Site-specific ethics boards have approved the study. All participants will provide informed consent. The research team will take an integrated approach to knowledge translation.

## Strengths and limitations of this study

- The mixed methods approach will evaluate the application of decision analysis to shared decision making surrounding prophylactic low molecular weight heparin (LMWH) for women who are pregnant or considering pregnancy and have experienced a venous thromboembolism (VTE) for whom guidelines recommend a shared decision-making process regarding thromboprophylaxis.
- Women who are pregnant or considering pregnancy and have experienced a VTE will be specifically targeted since guidelines recommend that treatment decisions regarding prophylactic LMWH be made using a shared decision-making process.
- The integration of quantitative and qualitative research methods to evaluate a complex intervention will offer greater insights than either method alone.
- A small sample size and the recruitment of participants from two high-income countries limits the generalisability of study findings.
- The results of this pilot study will be used to inform a randomised controlled trial.

## INTRODUCTION

### Thromboprophylaxis during pregnancy

Venous thromboembolism (VTE) is a condition in which a blood clot forms in the deep veins of the leg, groin or arm (deep vein thrombosis (DVT)) and travels to the lungs (pulmonary embolism (PE)). Globally, VTE is a leading cause of maternal morbidity and mortality.<sup>1,2</sup> In high-income countries, the incidence of VTE is 1.2 in 1000 pregnancies and deaths in 1.1 per 100 000 deliveries.<sup>3</sup> Women with prior VTE are at an increased risk of thrombosis during subsequent pregnancies,<sup>4,5</sup> although the magnitude of this risk remains uncertain given that the



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

#### Correspondence to

Dr Feng Xie;  
fengxie@mcmaster.ca and  
Dr Pablo Alonso-Coello;  
palonso@santpau.cat

existing evidence base is informed by studies with major limitations.<sup>6</sup>

Because it does not traverse the placenta and is associated with a low risk of heparin-induced thrombocytopaenia and osteopaenia, low molecular weight heparin (LMWH) represents the preferred treatment option for the prevention of VTE during pregnancy over other anti-thrombotic therapies, such as unfractionated heparin.<sup>7-9</sup> It is, however, expensive and requires daily subcutaneous injections.<sup>10</sup> Prophylactic LMWH may be associated with an increased risk of major bleeding, especially around the time of delivery and may limit access to regional analgesia.<sup>7,11</sup> There continue to be challenges in determining the appropriate pregnancy-specific dose and role of laboratory monitoring.

Due to uncertainty regarding available evidence as well as the costs associated with administration and monitoring, the American Society of Hematology recommends that the decision between prophylactic LMWH during pregnancy versus expectant management involving no LMWH be made using a shared decision-making process.<sup>9</sup> The use of decision aids is suggested for this type of conditional recommendation (ie, recommendation based on weak evidence) as they may help individuals make decisions consistent with their risks, values and preferences. Despite this call for shared decision-making, a paucity of decision support tools exist to help patients engage in treatment decisions for VTE.<sup>12</sup>

### Shared decision making and the clinical encounter

Shared decision-making is a continuum process through which patients and clinicians work together to make a treatment decision.<sup>13</sup> Although there is no consensus regarding the definition of shared decision-making,<sup>14</sup> three elements are considered necessary: (1) recognising a decision is required; (2) knowing and understanding the best available evidence; and (3) incorporating patient values and preferences into the decision.<sup>15</sup> Although a key element is the incorporation of patient values and preferences into the decision,<sup>15</sup> studies indicate they are often ignored or poorly understood by providers.<sup>16,17</sup>

A number of decision support technologies to facilitate shared decision-making exist. Decision aids are the most commonly used tool. Available in a variety of formats (eg, online, print and video), decision aids are meant to inform patients regarding treatment options and their associated potential benefits, harms and costs.<sup>18,19</sup> These tools often entail an implicit method of values clarification, in which patients are encouraged to think about what's important to them.<sup>20</sup> A systematic review of 105 randomised controlled trials involving 31 043 patients found that, while decision aids helped patients make more informed decisions,<sup>21</sup> there is uncertainty as to how these tools support the process of integrating patient values and preferences into the decision-making process.

The International Patient Decision Aid Standards Collaboration recommends that decision aids include a value elicitation exercise alongside the presentation of

evidence.<sup>22</sup> A variety of methods can help patients appraise their values regarding treatment options under consideration. For example, patients can complete a ranking exercise to express the relative importance of each outcome. Although eliciting patients' values is important, it does not ensure that they are incorporated into the decision-making process. Furthermore, patients and providers then face the cognitive challenge of weighing the harms and benefits of each treatment option alongside their probabilities of occurring and the patient's values and preferences.<sup>23-25</sup>

### Decision analysis

Decision analysis is a decision support technology that could bridge the gap between decisions based solely on evidence and the values and preferences of individual patients. It involves structuring a decision problem using an analytical framework (eg, decision tree) that includes key clinical outcomes associated with each treatment option as well as the natural course of untreated illness along with their associated probabilities and utilities or other weighting factors based on patients' values and preferences. Probabilities, a measure of likelihood that an event will occur,<sup>26</sup> are obtained from published studies and may themselves be personalised based on individual patient's clinical risk profile. Values and preferences for health outcomes, which are expressed as health utilities, can be obtained directly from patients.<sup>27</sup> Utility assessment involves comparisons to anchor health states (ie, perfect health and death) and may involve gambles that entail a risk of undesirable outcomes, or trade-offs between quality and quantity of life. Utility scores can be elicited directly from patients using exercises such as the standard gamble, time trade-off and visual analogue scale.<sup>28</sup> Utility scores typically are anchored 1 representing 'perfect health' and 0 representing the 'dead' state. Utility scores can be used in a personalised decision analysis to calculate the quality-adjusted life years (QALYs) for each treatment option under consideration. For example, if a treatment results in a life expectancy of 10 years, but the quality of life for the resulting health state has a utility of 0.9, the treatment would yield 9.0 QALYs. If multiple treatment options are being considered, the treatment with the highest quality-adjusted life expectancy represents the best option.<sup>27</sup> Thus, patient-specific probabilities and utility scores can be used in a decision analysis to calculate personalised results and obtain an explicit guidance statement to facilitate decision making.<sup>29,30</sup>

### Decision analysis for shared decision making

Several studies found a disagreement between the results of the decision analysis and treatment guidelines.<sup>31-33</sup> This suggests that guidelines, despite including a range of inputs (clinical evidence and patient preferences) and potential outcomes, might not adequately respond to individual patient treatment decisions.

Current evidence, although limited, shows the potential for personalised decision analysis to improve shared

decision making in clinical contexts.<sup>31–41</sup> While decision analysis is increasingly being used to inform the management of pregnancy-related conditions,<sup>42</sup> its use is fraught with challenges. These include competing interests of mother and fetus, the use of appropriate time horizons and challenges with using QALYs as an outcome measure for combined maternal–fetal health states.<sup>43</sup> As a result, it is unclear how or if decision analysis should be incorporated within shared decision making surrounding VTE and pregnancy, which necessitates a robust approach to shared decision-making given the close balance between benefits and harms of LMWH and limitations of available evidence.

### Objective

The objective of this study is to explore the application of decision analysis to a shared decision-making process for the decision of using prophylactic LMWH for pregnant women or those considering pregnancy who have experienced a VTE. The study will also inform the design and execution of a future randomised controlled trial that will evaluate the additional value of decision analysis in the clinical encounter for the same decision.

### METHODS AND ANALYSIS


In this study, we will use an explanatory sequential mixed methods design, which consists of quantitative data collection and analysis followed by qualitative data collection and analysis. This type of study design will allow for a comprehensive evaluation of decision analysis within a shared decision-making encounter for VTE and pregnancy.

In a mixed methods study, separate research questions are specified for the quantitative and qualitative components of the study, as well as an overarching mixed

methods question.<sup>44</sup> The following research questions will guide the conduct of this study:

- Quantitative research question
  - Using a shared decision-making process that incorporates decision analysis, what is the level of decision quality among women that are pregnant or considering pregnancy who have experienced VTE and must decide whether to take LMWH?
- Qualitative research question
  - What are the experiences and perceptions related to a shared decision-making process that incorporates decision analysis among women that are pregnant or considering pregnancy who have experienced VTE and must decide whether to take LMWH?
- Mixed methods research question
  - How do the qualitative findings provide an enhanced understanding of quantitative results on decision quality to evaluate the application of decision analysis to a shared decision-making process among women who are pregnant or considering pregnancy and have experienced a VTE and must decide whether to take LMWH?

**Figure 1** presents the study flow of this multicentre, single-arm, intervention pilot study. In step I, we will administer the intervention and measure decision quality among women who are pregnant or considering pregnancy and have experienced a VTE and must decide whether to take prophylactic LMWH. Step II follows the analysis of quantitative data, whereby we will use the quantitative results to inform qualitative data collection. In step III, we will conduct a qualitative descriptive study with all participants to explore their experiences and perceptions related to the intervention. In step IV, we will integrate findings from the quantitative and qualitative



**Figure 1** Study flow diagram for the DASH-TOP study. DASH-TOP, Decision Analysis in SHared decision making for Thromboprophylaxis during Pregnancy.



analyses to obtain inferences that add insight beyond what could be understood from either dataset on their own (meta-inferences).<sup>44</sup>

### **Step I: administration of intervention and quantitative data collection**

#### **Study design**

In step I, we will ask women who are pregnant or considering pregnancy and have experienced VTE to participate in a shared decision-making intervention for prophylactic LMWH. The intervention will use a personalised decision analysis as a complementary approach to a decision aid. Since this study aims to pilot test the use of the decision analysis tool and explore preliminary findings, a control group was not included because the study was not designed to compare effects between intervention and control groups.

#### **Study setting**

The study will recruit women from hospitals in Canada (n=2 sites) and Spain (n=4 sites). The decision to conduct an international study was made in consideration of the small size of the target population. Since it is estimated that complications due to VTE occur in approximately 1 in 1000 pregnancies,<sup>45</sup> an international study will increase feasibility of recruitment and generalisability of results.

In a previous study conducted by the research team, we compared the use of direct choice and decision analysis among 123 women with a history of VTE who were pregnant or planning pregnancy. During this study, we observed some differences between countries, including Canada and Spain.<sup>46</sup> Given that the research teams in these two countries have conducted similar studies together and staff at the selected study sites are already trained, these two countries were selected for the pilot sites.

#### **Participants**

The target population consists of women with a prior VTE who are pregnant or planning pregnancy and who have been referred for counselling regarding prophylactic LMWH. Women will be eligible for inclusion if they have a history of lower extremity DVT or PE, are currently pregnant or planning pregnancy and considering LMWH. Women will be excluded from the study if they are currently receiving thromboprophylaxis or therapeutic anticoagulation, are less than 18 years of age, have contraindications or intolerances to LMWH, or are unwilling and/or unable to provide informed consent. At each site, the clinician will review medical charts to identify eligible women based on their pregnancy status and presence of a previous blood clot. The clinician will contact potential participants and ask if they are willing to be approached by a member of the research. With the woman's permission, the research team will contact the woman by telephone to explain the study, confirm eligibility and schedule the interview.

Since greater priority will be given to the qualitative component of this mixed methods study, the sample size will be determined in consideration of the amount of information required to address the qualitative research question.<sup>47</sup> There are no formal rules for calculating a priori a sample size for qualitative studies, instead an estimate of the number of participants required is provided. We have estimated that we will need an initial purposeful sample of 30 women (n=5 per site) given that this is a fairly homogenous population of women with respect to their medical diagnoses and who are making these decisions within pregnancy. However, as data collection and analysis is concurrent in qualitative studies, if we determine towards the end of our recruitment that certain concepts are not fully saturated, then the decision will be made to continue recruitment until we reach saturation or 'the point at which the data collection process no longer offers any new or relevant data'.<sup>48</sup>

#### **Intervention**

The intervention will explore the decision-making process comparing strategies of administering prophylactic LMWH once daily when pregnancy is confirmed and continuing until delivery<sup>7</sup> versus expectant management without LMWH. The intervention has been designed with three components: a direct choice exercise, values elicitation exercise and personalised decision analysis. All participants in the study will receive the intervention. A member of the research team will deliver the intervention and collect data in person or online using a web-based platform. The process is expected to take between 1 and 1.5 hours. Through this interview, some women may find the additional counselling and information received helpful in making their decision about the use of LMWH. All women will participate in the study prior to meeting with their healthcare provider so that they can apply this new information to their decision and follow-up with a healthcare professional if they have any questions. We do not anticipate there is any risk associated with this interview in general nor with the length of time required to complete the interview; however, we do inform participants that they can stop participation at any point during the intervention and are free to not respond to questions they are uncomfortable with.

To start, women will be asked to consider four health states relevant to this decision: (1) use of LMWH; (2) major obstetrical bleed; (3) DVT; and (4) PE. Health state descriptions are available in online supplemental appendix 1. Women will then complete a direct choice exercise that includes the review of an interactive electronic decision aid developed using the MagicApp platform.<sup>49</sup> The decision aid describes the harms and benefits of LMWH for prevention of pregnancy-related VTE. In line with International Patient Decision Aid Standards (IPDAS) recommendations, information is presented in numeric and graphic format.<sup>22</sup> Figure 2 presents a screenshot of the decision aid.

## Deep Vein Thrombosis (DVT)

Among a 1000 patients like you, with antepartum anticoagulant prophylaxis with low molecular weight heparin (LMWH)




**Figure 2** Screenshot of decision aid. This screenshot presents women with their estimated risk of experiencing a deep vein thrombosis (DVT). Risks are presented in both numerical and graphical format. Numerically, the risk of DVT during pregnancy is 5.5%. This means that, out of 1000 women, approximately 55 will experience a DVT if they do not take low molecular weight heparin (LMWH) and 9 will experience a DVT if they do take LMWH. Overall, 46 fewer women will experience a blood clot when taking LMWH compared with not taking LMWH. The graphic represents a room of 1000 women. The 945 figures who are coloured in grey represent those women who were not destined to experience a DVT and would take daily injections of medication for the rest of their pregnancy with no benefit. The nine black figures represent women who will take the medication regularly and still experience a DVT during pregnancy because LMWH is not 100% effective. The orange figures represent the 46 women who would have experienced a DVT in their pregnancy and will avoid the blood clot because they took LMWH. The overall certainty of the evidence informing these estimates is low due to the types of studies that were conducted and the small sample sizes.

The direct choice exercise will be followed by three value elicitation exercises (rank ordering, visual analogue scale and standard gamble)<sup>50</sup> that will be completed using Gambler II software.<sup>51</sup> Women will consider the four health states listed above. For the ranking exercise, women will rank the health states from most to least preferred. For the visual analogue scale, women will place each health state along a ‘feeling thermometer’ that represents their preference on a scale of 0 (dead) to 100 (perfect health). Figure 3 presents a screenshot of the visual analogue scale exercise. The standard gamble uses a poison pill analogy to describe a gamble in which the patient can accept an intermediate health state, such as a PE, or take a medication that can prevent that from occurring. The patient need only take a single pill from the bottle, but unfortunately some varying number of pills in the bottle are ‘poison’ and may result in death. If a patient is indifferent between, for instance, a 0.1 risk of getting a poison pill to avoid a PE and prophylactic LMWH, then the utility of that health state would be calculated as (1–0.1) or 0.9.<sup>35</sup> Death will be used as the anchor for standard gambles relating to major obstetrical bleed, DVT and PE health states. In the standard gamble for the use of LMWH, DVT will be the anchor.

The visual analogue scale and ranking tasks will serve as warm-up exercises, with the standard gamble determining the value rating inputted into the decision analytic model. The standard gamble is considered to be a gold standard in preference elicitation methods as it has demonstrated acceptability and reliability,<sup>52 53</sup> as well as established theoretical underpinnings of expected utility theory.<sup>54 55</sup> Unlike ranking and the visual analogue scale, it evaluates preferences under conditions of uncertainty.

Once the utilities for a given patient have been obtained, they will be inputted into the decision analytic model along with patient-specific probabilities for VTE risk sourced from clinical guidelines.<sup>9</sup> The decision analytical model is a Markov state transition model that examines two treatment options under consideration: prophylactic LMWH versus expectant management without LMWH.<sup>10</sup> The model has a lifetime time horizon and a 6-week cycle length to simulate both antepartum and lifetime events. The model will be personalised according to women’s age and risk of VTE and utilities for each health state.<sup>56 57</sup> Based on this information, the decision analytical model will estimate the QALYs for each treatment option. The treatment with the greatest expected QALYs will represent the recommended



**Figure 3** Screenshot of visual analogue scale. This screenshot demonstrates a visual analogue scale where participants are asked to place each health state along a ‘feeling thermometer’ that represents their preference on a scale of 0 (dead) to 100 (perfect health). In this hypothetical example, pulmonary embolism, deep vein thrombosis and major bleed are rated as 20, 30 and 50 out of 100, respectively.

strategy. **Figure 4** presents a screenshot of the decision analysis recommendation.

#### Data collection


At the start of the study, the research team will document women’s age, level of education, pregnancy status, pregnancy number, details regarding prior VTE (eg, type of event and presence of precipitating clinical risk factors), type and duration of treatment for prior VTE, and experience with LMWH (eg, bruising and heparin-induced thrombocytopenia).

After completing the direct choice, values elicitation exercises and receiving the results of their personalised decision analysis, women will be asked to make a preliminary treatment decision. Women will make a final decision during the consultation with their provider. Women will complete a self-administered questionnaire to evaluate decision quality using the Modified Decisional Conflict Scale,<sup>58</sup> Decision Self-Efficacy Scale<sup>59–61</sup> and Satisfaction with Decision Scale.<sup>62</sup> The Decisional Conflict Scale is a 16-item instrument that includes five subscales: informed, values, support, uncertainty and effective decision. Response options, which range from 0 for ‘strongly agree’ to 4 for ‘strongly disagree’, are combined into a summary score that ranges from 0 to 100, with 100 indicating an extremely high level of decisional conflict. The

Decision Self-Efficacy Scale is an 11-item instrument that measures confidence or belief in one’s ability in decision making. Items are given a value between 0 and 4, with 0 indicating ‘not at all confident’ and 4 ‘very confident’. These values are combined into a summary score that ranges from 0 for ‘not confident’ to 100 for ‘extremely confident’. The Satisfaction with Decision Scale measures satisfaction with healthcare decisions. It is a six-item instrument that generates a summary score, ranging from 6 for ‘low level of decision satisfaction’ to 30 for ‘high level of decision satisfaction’. While it is acknowledged that these measures of decision quality have limitations,<sup>63</sup> they are widely used and have been validated in different patient populations.<sup>58 64–68</sup> Selecting three measures will provide a starting point for understanding different facets of the shared decision-making process. The self-administered questionnaire is available in online supplemental appendix 2.

#### Data analysis

We will use descriptive statistics to summarise women’s age, level of education, pregnancy status, number and characteristics of previous VTE and experience with LMWH. We will assess decision quality using the scores obtained from the Decisional Conflict Scale, Self-Efficacy Scale and Satisfaction with Decision Scale. We will



**Figure 4** Screenshot of decision analysis recommendation. This screenshot shows how the personalised decision analysis results are presented to participants. In this example, the decision analytic framework calculated that the average quality-adjusted life year (QALY) expected for treatment with low molecular weight heparin (LMWH) was  $-1$  compared with expectant management without LMWH. In this case, no LMWH would be the recommended strategy because it has the greatest expected QALYs and represents the treatment option that maximises the woman's quality of life based on available clinical evidence and the patient's preferences.

examine concordance between the woman's decision regarding LMWH and recommendation from the personalised decision analysis.

#### Step II: integration of quantitative results and planning of qualitative data collection

Based on the results of step I, women will be stratified into four categories according to their treatment decision (LMWH and no LMWH), decision analysis recommendation (LMWH and no LMWH) and the concordance/discordance between the two. **Figure 5** presents the categorisation matrix. This is a form of integration in mixed methods research where one dataset (ie, quantitative) is analysed and used to inform subsequent data collection (ie, qualitative).<sup>69</sup> The purpose is to identify what quantitative results need further explanation.

#### Step III: qualitative descriptive study

##### Study design

Step III is a qualitative descriptive study that will occur after the quantitative component is complete. Qualitative

description is a method of inquiry that explores individuals' perceptions and experiences of a phenomenon.<sup>70</sup> The aim is to generate rich and straightforward descriptions of an experience that is rooted in the language used by participants.<sup>71</sup>

##### Participants

After completion of the multicentre, single-arm, intervention study, all women will be invited to participate in the qualitative descriptive study.<sup>72</sup> Women will be stratified into four categories according to their treatment decision, decision analysis recommendation and the concordance/discordance between the two.

##### Data collection

In-depth, semistructured interviews will be conducted to explore women's experiences and perceptions as they relate to: (1) the decision-making process; (2) the direct choice exercise; (3) the personalised decision analysis; and (4) their knowledge of LMWH. Explicitly linking to the quantitative results, four versions of the interview

## Treatment decision

		LMWH	No LMWH
Decision analysis recommendation	LMWH	Concordant	Discordant
	No LMWH	Discordant	Concordant

**Figure 5** Categorisation matrix based on quantitative results. LMWH, low molecular weight heparin.

guide have been designed to address women's treatment decision, decision analysis recommendation and the concordance/discordance between the two. The interview guide was developed and tested by the research team, which comprised clinicians, patients and researchers with expertise in pregnancy-related VTE, shared decision making and qualitative methods. It is available in online supplemental appendix 3. A member of the research team will conduct the interviews, which will be audio-recorded and transcribed verbatim.

#### Data analysis

Data from the interviews will be analysed using a method of thematic analysis. Thematic analysis refers to the systematic search for and identification of themes that are present in data.<sup>73</sup> The aim is to obtain an understanding of a phenomenon by identifying themes or patterns through a process of coding.<sup>74</sup> Given the exploratory nature of this qualitative descriptive study, there will be no predetermined coding scheme.

Two members of the research team with training in qualitative analyses will conduct the thematic analysis following the six-step approach outlined by Braun and Clarke<sup>75</sup> (ie, familiarising with the data, generating initial codes, searching for themes, reviewing the themes, defining and naming themes and producing the final report). This process entails an iterative analysis within and across the transcripts of women from each of the four groups outlined in figure 5 to gain insight into why there is concordance/discordance between treatment decisions and decision analysis recommendations among pregnant women with a previous VTE.<sup>46</sup>

Looking for overarching themes and relations between them, the investigators will independently code a sample of the transcripts independently to generate an initial codebook and definitions. They will meet with a third study investigator to discuss emerging themes and definitions of codes until consensus on a codebook is reached.

To ensure reliability, two team members will code the transcripts using this codebook. They will document and discuss any inconsistencies. NVivo software<sup>76</sup> will facilitate this analysis. Qualitative data collection and coding will be conducted in the language of origin. Canadian and Spanish team members will work collaboratively on developing a single codebook for the Spanish and English analyses, discussing emerging themes and discrepancies as part of this process. An investigator with proficiency in English and Spanish will compare the summaries of findings and write a synthesis of themes that highlights important differences if they exist.

#### Step IV: integration of quantitative and qualitative findings

Once the quantitative and qualitative analyses have been analysed separately, the findings will be integrated using a joint display. A joint display is a table in which the quantitative and qualitative data are displayed alongside each other to enable an explicit comparison between datasets.<sup>44</sup> This is a form of integration at the interpretive level, whereby each data set remains analytically separate from the other.<sup>77</sup> The intent is to give a voice to study participants and ensure that quantitative findings are grounded in participants' experiences.

The joint display will present each theme from the qualitative analyses according to the mean scores obtained from the Decisional Conflict Scale, Self-Efficacy Scale and Satisfaction with Decision Scale as well as the women's risk of VTE, utility values, treatment decision and decision analysis recommendation. If there are any outliers or differences across groups, the integrated analyses will aim to explain these through qualitative data. For example, qualitative data can be used to explore any inconsistencies in utility values that are produced by the standard gamble and inputted into the decision analytic framework.

There are many reasons an inconsistency could occur. Pregnancy can be accompanied by extreme risk aversion,<sup>78</sup> which could skew the standard gamble utility value

**Table 1** Checklist of strategies to ensure rigour in the conduct and reporting of the study

Research step	Criteria	Action taken
Quantitative component	Dependability	Data collection will be conducted using standardised scripts.
	Credibility and confirmability	Reflexive notes will be taken during data collection to record situational information.
	Confirmability	Reasons for non-participation will be noted.
	Confirmability	All statistical analyses will be performed according to a prespecified protocol.
Qualitative component	Dependability	Data collection will be conducted using standardised scripts.
	Confirmability	Reasons for loss to follow-up will be noted.
	Credibility and confirmability	Reflexive notes will be taken during data collection to record situational information.
	Dependability	A sample of the transcripts (eg, 10%) from each site will be checked against the audio recordings.
	Credibility	More than one person will be involved in the analysis of interview data.
	Credibility	Persons involved in the analysis of interview transcripts will look for disconfirming data while developing themes to ensure that all aspects of the interviews were considered.
	Dependability	An investigator with proficiency in English and Spanish will compare the English and Spanish findings.
Mixed methods component	Credibility	The justification for using a mixed methods approach to answer the research question(s) will be described.
	Credibility	The study design will be described in terms of the purpose, priority and sequence of methods.
	Credibility	The process of integration will be described in terms of where it occurred, how it occurred and who participated in it.
	Credibility	The limitation of one method associated with the presence of the other method will be described.
	Credibility	Insights gained from mixing or integrating methods will be described.
	Credibility	The integration of quantitative and qualitative research methods will occur at multiple points of the mixed methods study (eg, research question, sampling strategy and analysis).
	Confirmability and dependability	Each data source will be triangulated to confirm convergence or divergence across datasets and study sites.
	Credibility	Inconsistencies between quantitative and qualitative findings will be explored.
	Credibility	The inferences derived from the quantitative and qualitative findings will be incorporated into meta-inferences.
	Confirmability	An audit trail will be maintained by the research coordinator to document all study decisions (and their rationale) and all sampling, data collection and analysis procedures implemented.
Entire study	Confirmability	Any deviations from the published protocol will be noted and justified to promote transparency of the research methods.

and subsequent treatment recommendation. A qualitative evaluation of a shared decision-making intervention in atrial fibrillation reported that patients struggled to grasp the standard gamble concept,<sup>79</sup> which could result in utility values that are not representative of patients' preferences. By leveraging qualitative data on women's experiences and perceptions of the intervention and decision-making process, integration will enable the research team to obtain meta-inferences and a deeper understanding of the application of decision analysis to shared decision making surrounding LMWH for

pregnant women or those considering pregnancy who have experienced a VTE.

A joint display is an important tool for establishing the relationship between intervention effects and the patient experience. If the analysis identifies contradictions between quantitative and qualitative findings,<sup>80</sup> we will verify the methodological rigour of each component of the study, the comparability of datasets and the delivery of the intervention.<sup>81</sup> We will also consider how these contradictions can generate new research questions.<sup>82</sup>



## Methodological rigour

Although an international study ensures feasibility of recruitment, it poses a challenge of maintaining consistency in data collection across sites. We have taken several steps in the planning of this study to mitigate this issue. At each site, we will have highly qualified personnel who have experience working on a shared decision-making project for VTE prophylaxis. Professional translation agencies have translated the scripts and interview guides developed in English into Spanish. Data collection materials have been tested with three to five patients at each site to ensure adequate understanding. To facilitate a standardised approach for administering the intervention, we have developed scripts based on feedback from patients, nurses and clinicians. All members of the research team will receive training on how to use required software programs.

Once recruitment starts, a range of strategies will be used to verify credibility (internal validity), dependability (reliability or consistency of findings) and confirmability (neutrality) of data. A list of these strategies is presented in *table 1*. Given the complexity of mixed methods research,<sup>83</sup> the rigour of the quantitative, qualitative and mixed methods components of the study will be assessed separately.<sup>84</sup>

## PATIENT AND PUBLIC INVOLVEMENT

Three patients (one from Spain and two from Canada) joined the study team as patient advisors. The Canadian Venous Thromboembolism Clinical Trials and Outcomes Research Network allowed our team to use their Partners Platform to recruit two Canadian patient-advisors. As part of this programme, patients receive training on how to participate in the research process. For the Spanish site, a patient who is also nurse at one of the participating hospitals was asked to participate as an advisor.

The three patient advisors matched inclusion criteria for the study. They reviewed all study materials and met with the research team to provide feedback on the study design, intervention, scripts and data collection materials. The development of the qualitative research questions and selection of quantitative outcome measures were directly informed by these patients' priorities, experience and preferences. An additional five patients participated in preliminary testing of the intervention to provide feedback on the overall research process and ensure adequate understanding.

Patients will not be directly involved in the recruitment and conduct of the study. The results of the decision analysis will be communicated with patients participating in the study. Additional study materials (ie, print outs of decision aid and health state descriptions) and published results will be made available to participants on request.

## ETHICS AND DISSEMINATION

Site-specific ethics boards have approved the study.

This study takes an integrated approach to knowledge translation that applies the principles of knowledge translation to the entire research process.<sup>85</sup> Eight patients have contributed to the design and pretesting of data collection materials. We will publish findings in peer-reviewed journals and present at key conferences, including meetings of the American Society of Hematology, International Society on Thrombosis and Haemostasis, Society of Medical Decision Making and Guidelines International Network. We will also disseminate results within the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) community.

### Author affiliations

<sup>1</sup>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada

<sup>2</sup>Iberoamerican Cochrane Center, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain

<sup>3</sup>Department of Pediatrics, Obstetrics, Gynaecology and Preventive Medicine, Universidad Autónoma de Barcelona, Barcelona, Catalunya, Spain

<sup>4</sup>Department of Medicine, McMaster University, Hamilton, Ontario, Canada

<sup>5</sup>Division of General Internal Medicine and Center for Clinical Effectiveness, University of Cincinnati, Cincinnati, Ohio, USA

<sup>6</sup>Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

<sup>7</sup>Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada

<sup>8</sup>Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada

<sup>9</sup>Departments of Medicine, Laboratory Medicine and Pathobiology, Institute of Health Policy Management and Evaluation, University of Toronto, Division of Hematology, Mount Sinai Hospital, Toronto, Ontario, Canada

<sup>10</sup>School of Nursing, McMaster University, Hamilton, Ontario, Canada

<sup>11</sup>CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

<sup>12</sup>Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario, Canada

**Twitter** Feng Xie @fengxie\_mac

**Acknowledgements** The authors wish to acknowledge and thank the patient advisors who contributed to the design of the study and testing of the data collection materials.

**Contributors** The study concept and design were conceived by FX, PA-C, GG, SB and ME. ME developed the intervention, with support from FX, PA-C, BH, ML-G and SB. BH developed the data collection materials and plan for data analyses, with support from FX, PA-C, GG, ME, ML-G, SB, RD, NS and SJ. BH prepared the first draft of the manuscript. All authors have reviewed the manuscript for critically for important intellectual content and offer final approval.

**Funding** BH received a doctoral award from the Canadian Institutes for Health Research (Grant number: GSD – 152327). The study is partially funded by the Spanish Public Research Institute – Health Institute Carlos III (Grant number: PI17/01874).

**Competing interests** ME has received grant funding from the National Institutes of Health (Eunice Kennedy Shriver National Institute of Child Health and Human Development, and National Center for Advancing Translational Sciences) and funding for investigator-initiated research from Bristol-Myers Squibb. RD has received speaking honoraria and grant funding from Ferring Inc and an early career grant from the Canadian Institutes for Health Research for projects unrelated to this study. NS has received honoraria and an educational grant from Sanofi. ML-G receives doctoral support from the Spanish Public Research Institute – Health Institute Carlos III. SB has acted as a consultant for Leo Pharma Canada (manufacturer of low molecular weight heparin) and receives unencumbered salary support through the McMaster University Eli Lilly Canada-May Cohen Chair in Women's Health.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.



**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iD

Feng Xie <http://orcid.org/0000-0003-3454-6266>

#### REFERENCES

- 1 James AH, Jamison MG, Brancazio LR, et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. *Am J Obstet Gynecol* 2006;194:1311–5.
- 2 Knight M, Nair M, Tuffnell D, eds. *Saving Lives, Improving Mothers' Care - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2013–15*. Oxford: National Perinatal Epidemiology Unit, University of Oxford, 2017.
- 3 Kourlaba G, Relakis J, Kontodimas S, et al. A systematic review and meta-analysis of the epidemiology and burden of venous thromboembolism among pregnant women. *Int J Gynaecol Obstet* 2016;132:4–10.
- 4 De Stefano V, Martinelli I, Rossi E, et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. *Br J Haematol* 2006;135:386–91.
- 5 Pabinger I, Grafenhofer H, Kaider A, et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. *J Thromb Haemost* 2005;3:949–54.
- 6 King A, D'Souza R, Herman D. *Outcome reporting in studies on the management and prevention of pregnancy-associated venous thromboembolism: a systematic review*. Manuscript submitted for publication.
- 7 Bates SM, Greer IA, Middeldorp S, et al. Vte, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. *Chest* 2012;141:e691S–736.
- 8 Zheng J, Chen Q, Fu J, et al. Critical appraisal of international guidelines for the prevention and treatment of pregnancy-associated venous thromboembolism: a systematic review. *BMC Cardiovasc Disord* 2019;19:199.
- 9 Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. *Blood Advances* 2018;2:3317–59.
- 10 Johnston JA, Brill-Edwards P, Ginsberg JS, et al. Cost-Effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism. *Am J Med* 2005;118:503–14.
- 11 Greer IA, Nelson-Piercy C. Low-Molecular-Weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. *Blood* 2005;106:401–7.
- 12 Barnes GD, Izzo B, Conte ML, et al. Use of decision AIDS for shared decision making in venous thromboembolism: a systematic review. *Thromb Res* 2016;143:71–5.
- 13 Coulter A. Partnerships with patients: the pros and cons of shared clinical decision-making. *J Health Serv Res Policy* 1997;2:112–21.
- 14 Makoul G, Clayman ML. An integrative model of shared decision making in medical encounters. *Patient Educ Couns* 2006;60:301–12.
- 15 Légaré F, Wittman HO. Shared decision making: examining key elements and barriers to adoption into routine clinical practice. *Health Aff* 2013;32:276–84.
- 16 Mulley AG, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients' preferences matter. *BMJ* 2012;345:e6572.
- 17 Mühlbacher AC, Juhnke C. Patient preferences versus physicians' judgement: does it make a difference in healthcare decision making? *Appl Health Econ Health Policy* 2013;11:163–80.
- 18 Akl EA, Oxman AD, Herrin J, et al. Framing of health information messages. *Cochrane Database Syst Rev* 2011;22: Cd006777.
- 19 Trevena LJ, Zikmund-Fisher BJ, Edwards A, et al. Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers. *BMC Med Inform Decis Mak* 2013;13 Suppl 2:S7.
- 20 Fagerlin A, Pignone M, Abhyankar P, et al. Clarifying values: an updated review. *BMC Med Inform Decis Mak* 2013;13 Suppl 2:S8.
- 21 Stacey D, Légaré F, Lewis K, et al. Decision AIDS for people facing health treatment or screening decisions. *Cochrane Database Syst Rev* 2017;19: Cd001431.
- 22 Elwyn G, O'Connor A, Stacey D, et al. Developing a quality criteria framework for patient decision AIDS: online international Delphi consensus process. *BMJ* 2006;333:417.
- 23 Albisser Schleger H, Oehninger NR, Reiter-Theil S. Avoiding bias in medical ethical decision-making. lessons to be learnt from psychology research. *Med Health Care Philos* 2011;14:155–62.
- 24 Redelmeier DA, Rozin P, Kahneman D. Cognitive and emotional perspectives. *Jama* 1993;270:72–6.
- 25 Tversky A, Kahneman D. Judgment under uncertainty: Heuristics and biases. *Science* 1974;185:1124–31.
- 26 Briggs AH, Claxton K, Sculpher MJ. *Decision modelling for health economic evaluation*. Oxford University Press, 2006.
- 27 Thompson C, Dowding D. *Essential decision making and clinical judgement for nurses E-Book*: Elsevier health sciences, 2009.
- 28 Soekhai V, Whichello C, Levitan B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. *Drug Discov Today* 2019;24:1324–31.
- 29 Weinstein MC, Torrance G, McGuire A. QALYs: the basics. *Value Health* 2009;12 Suppl 1:S5–9.
- 30 Brazier J. Valuing health states for use in cost-effectiveness analysis. *Pharmacoconomics* 2008;26:769–79.
- 31 Man-Son-Hing M, Laupacis A, O'Connor AM, et al. Patient preference-based treatment thresholds and recommendations: a comparison of decision-analytic modeling with the probability-tradeoff technique. *Med Decis Making* 2000;20:394–403.
- 32 Montgomery AA, Harding J, Fahey T. Shared decision making in hypertension: the impact of patient preferences on treatment choice. *Fam Pract* 2001;18:309–13.
- 33 Protheroe J, Fahey T, Montgomery AA, et al. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. *BMJ* 2000;320:1380–4.
- 34 Bekker HL, Hewison J, Thornton JG. Applying decision analysis to facilitate informed decision making about prenatal diagnosis for Down syndrome: a randomised controlled trial. *Prenat Diagn* 2004;24:265–75.
- 35 Eckman MH, Wise RE, Naylor K, et al. Developing an atrial fibrillation guideline support tool (AFGUST) for shared decision making. *Curr Med Res Opin* 2015;31:603–14.
- 36 Clancy CM, Cebul RD, Williams SV. Guiding individual decisions: a randomized, controlled trial of decision analysis. *Am J Med* 1988;84:283–8.
- 37 Eckman MH, Costea A, Attari M, et al. Shared decision-making tool for thromboprophylaxis in atrial fibrillation - A feasibility study. *Am Heart J* 2018;199:13–21.
- 38 Montgomery AA, Emmett CL, Fahey T, et al. Two decision AIDS for mode of delivery among women with previous caesarean section: randomised controlled trial. *BMJ* 2007;334:1305.
- 39 Montgomery AA, Fahey T, Peters TJ. A factorial randomised controlled trial of decision analysis and an information video plus leaflet for newly diagnosed hypertensive patients. *Br J Gen Pract* 2003;53:446–53.
- 40 Sacchi L, Rubrichi S, Rognoni C, et al. From decision to shared-decision: introducing patients' preferences into clinical decision analysis. *Artif Intell Med* 2015;65:19–28.
- 41 Thomson P, Dowding D, Swanson V, et al. A computerised guidance tree (decision aid) for hypertension, based on decision analysis: development and preliminary evaluation. *Eur J Cardiovasc Nurs* 2006;5:146–9.
- 42 D'Souza R, Bonasia K, Shah PS, et al. Clinical decision analysis and model-based economic evaluation studies in perinatology: a systematic review. *Acta Obstet Gynecol Scand* 2019;98:967–75.
- 43 D'Souza R, Shah PS, Sander B. Clinical decision analysis in perinatology. *Acta Obstet Gynecol Scand* 2018;97:491–9.
- 44 Creswell JW, Clark VLP. *Designing and conducting mixed methods research*. SAGE Publications, 2018.
- 45 Andersen BS, Steffensen FH, Sorensen HT, et al. The cumulative incidence of venous thromboembolism during pregnancy and



- puerperium-an 11 year Danish population-based study of 63,300 pregnancies. *Acta obstetricia et gynecologica Scandinavica* 1998;77:170–3.
- 46 Eckman MH, Alonso-Coello P, Guyatt GH, et al. Women's values and preferences for thromboprophylaxis during pregnancy: a comparison of direct-choice and decision analysis using patient specific utilities. *Thromb Res* 2015;136:341–7.
- 47 Bengtsson M. How to plan and perform a qualitative study using content analysis. *NursingPlus Open* 2016;2:8–14.
- 48 Dworkin SL. Sample size policy for qualitative studies using in-depth interviews. *Arch Sex Behav* 2012;41:1319–20.
- 49 Magic. A digital authoring and publication platform for the evidence ecosystem, by magic evidence ecosystem Foundation, 2020. Available: <http://www.magicapp.org>
- 50 Gafni A. The standard gamble method: what is being measured and how it is interpreted. *Health Serv Res* 1994;29:207–24.
- 51 Adejare AA, Eckman MH. Automated tool for health utility assessments: the gambler II. *MDM Policy Pract* 2020;5:2381468320914307:238146832091430.
- 52 Green C, Brazier J, Deverill M. Valuing health-related quality of life. A review of health state valuation techniques. *Pharmacoeconomics* 2000;17:151–65.
- 53 Torrance GW. Utility approach to measuring health-related quality of life. *J Chronic Dis* 1987;40:593–600.
- 54 Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. *Socioecon Plann Sci* 1976;10:129–36.
- 55 Dolan P, Gudex C, Kind P, et al. Valuing health states: a comparison of methods. *J Health Econ* 1996;15:209–31.
- 56 Wess ML, Schauer DP, Johnston JA, et al. Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. *J Gen Intern Med* 2008;23:411–7.
- 57 Eckman MH, Singer DE, Rosand J, et al. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. *Circ Cardiovasc Qual Outcomes* 2011;4:14–21.
- 58 O'Connor AM. Validation of a decisional conflict scale. *Med Decis Making* 1995;15:25–30.
- 59 O'Connor AM, Tugwell P, Wells GA, et al. A decision aid for women considering hormone therapy after menopause: decision support framework and evaluation. *Patient Educ Couns* 1998;33:267–79.
- 60 O'Connor AM, Tugwell P, Wells GA, et al. Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy. *Med Decis Making* 1998;18:295–303.
- 61 O'Connor AM. *User Manual-Decision self efficacy scale*, 1995.
- 62 Holmes-Rovner M, Kroll J, Schmitt N, et al. Patient satisfaction with health care decisions: the satisfaction with decision scale. *Med Decis Making* 1996;16:58–64.
- 63 Scholl I, Loon MK-van, Sepucha K, et al. Measurement of shared decision making – a review of instruments. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2011;105:313–24.
- 64 Ferron Parayre A, Labrecque M, Rousseau M, et al. Validation of sure, a four-item clinical checklist for detecting decisional conflict in patients. *Med Decis Making* 2014;34:54–62.
- 65 Koedoot N, Molenaar S, Oosterveld P, et al. The decisional conflict scale: further validation in two samples of Dutch oncology patients. *Patient Educ Couns* 2001;45:187–93.
- 66 Lam WWT, Kwok M, Liao Q, et al. Psychometric assessment of the Chinese version of the decisional conflict scale in Chinese women making decision for breast cancer surgery. *Health Expect* 2015;18:210–20.
- 67 Linder SK, Swank PR, Vernon SW, et al. Validity of a low literacy version of the decisional conflict scale. *Patient Educ Couns* 2011;85:521–4.
- 68 Mancini J, Santin G, Chabal F, et al. Cross-Cultural validation of the decisional conflict scale in a sample of French patients. *Qual Life Res* 2006;15:1063–8.
- 69 Creswell JW, Klassen AC, Plano Clark VL. *Best practices for mixed methods research in the health sciences*. Office of Behavioral and Social Sciences Research (OBSSR), 2010.
- 70 Neergaard MA, Olesen F, Andersen RS, et al. Qualitative description - the poor cousin of health research? *BMC Med Res Methodol* 2009;9:52.
- 71 Sandelowski M. Whatever happened to qualitative description? *Res Nurs Health* 2000;23:334–40.
- 72 Charles C, Gafni A, Whelan T, et al. Cultural influences on the physician-patient encounter: the case of shared treatment decision-making. *Patient Educ Couns* 2006;63:262–7.
- 73 Guest G, MacQueen KM, Namey EE. *Applied thematic analysis*. SAGE Publications, 2011.
- 74 Boyatzis RE. *Transforming qualitative information: thematic analysis and code development*. SAGE Publications, 1998.
- 75 Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol* 2006;3:77–101.
- 76 QSR International Pty Ltd. NVivo (released in March 2020), 2020. Available: <https://www.qsrinternational.com/nvivo-qualitative-data-analysis-software/home>
- 77 Sandelowski M. Combining qualitative and quantitative sampling, data collection, and analysis techniques in mixed-method studies. *Res Nurs Health* 2000;23:246–55.
- 78 Ballantyne A, Gavaghan C, McMillan J, et al. Pregnancy and the culture of extreme risk aversion. *The American Journal of Bioethics* 2016;16:21–3.
- 79 Murtagh MJ, Thomson RG, May CR, et al. Qualitative methods in a randomised controlled trial: the role of an integrated qualitative process evaluation in providing evidence to discontinue the intervention in one arm of a trial of a decision support tool. *Qual Saf Health Care* 2007;16:224–9.
- 80 Zhang W, Creswell J. The use of "mixing" procedure of mixed methods in health services research. *Med Care* 2013;51:e51–7.
- 81 Moffatt S, White M, Mackintosh J, et al. Using quantitative and qualitative data in health services research - what happens when mixed method findings conflict? [ISRCTN61522618]. *BMC Health Serv Res* 2006;6:28.
- 82 Mbuagbaw L, Ongolo-Zogo P, Thabane L. Investigating community ownership of a text message programme to improve adherence to antiretroviral therapy and provider-client communication: a mixed methods research protocol. *BMJ Open* 2013;3:e002816–8.
- 83 Onwuegbuzie AJ, Johnson RB. The validity issue in mixed research. *Research in the Schools* 2006;13:48–62.
- 84 Creswell JW, Plano Clark VL. *Designing and conducting mixed methods research*. 3. Thousand Oaks, CA: SAGE Publications, 2018.
- 85 Canadian Institutes for Health Research. Guide to knowledge translation planning at CIHR: integrated and End-of-Grant approaches, 2020. Available: <https://cihr-irsc.gc.ca/e/45321.html#a3> [Accessed July 20 2020].

## Appendix A. Health state descriptions

### Health state description for taking low molecular weight heparin

<b>PRACTICAL ISSUES ABOUT TAKING LOW MOLECULAR WEIGHT HEPARIN (LMWH) TO PREVENT BLOOD CLOTS DURING PREGNANCY</b>	
 Pregnancy and nursing	<ul style="list-style-type: none"><li>• You will take low molecular weight heparin for the rest of your pregnancy.</li><li>• Because you are taking heparin, your doctor may need to make special plans for your delivery. If you go into labour when your blood is thinned, you may not be able to use the best way to reduce the pain of labour (a freezing needle in your back or epidural) and you may have a higher risk of bleeding. To prevent this, your doctor may decide that your delivery will be planned (also called an induction). If you go into labour early, your epidural may be delayed or you may not be able to receive one at all.</li><li>• There are no long-term risks for you or for your baby from taking low molecular weight heparin during your pregnancy.</li></ul>
 Medication routine	<ul style="list-style-type: none"><li>• You or a family member needs to learn to administer low molecular weight heparin using needles beneath the skin for the rest of your pregnancy.</li><li>• Your daily low molecular weight heparin needles may sting.</li><li>• You will continue low molecular weight heparin for at least 6 weeks after your baby is born, either with needles or with a tablet. If you choose the tablet, you will need to have blood tests on a regular basis to make sure you are using the right dose.</li></ul>
 Adverse effects, interactions and antidote	<ul style="list-style-type: none"><li>• You may get a bruise at the place where you used the needle.</li><li>• If you get a rash with the injections, you may need to use a different type of heparin. Less than 1% of pregnant women taking low molecular weight heparin will develop a more serious allergic reaction that can actually increase your risk of blood clots and will make it necessary to change to a different blood thinner.</li><li>• You may experience thinning of the bones. We think it is unlikely that this thinning of the bones will lead to an increased risk of fracture; however, we don't know this for sure.</li><li>• There are no long-term risks for you or for your baby from taking low molecular weight heparin during your pregnancy. Taking low molecular weight heparin does not increase your risk of miscarriage.</li></ul>

## Health state description for deep vein thrombosis

PREGNANCY-ASSOCIATED BLOOD CLOT IN LEG – DEEP VEIN THROMBOSIS (DVT)	
<b>Symptoms &amp; Signs</b>	<ul style="list-style-type: none"> <li>Your leg hurts and it swells. It hurts more if you go for more than a short walk.</li> </ul>
<b>Diagnosis &amp; Treatment</b>	<ul style="list-style-type: none"> <li>Your doctor does an ultrasound test that shows that you have a blood clot leg. You stay in the Emergency Department overnight.</li> <li>You worry about the bad things that may happen to your baby because of this blood clot.</li> <li>Your doctor treats you with blood thinning needles of low molecular weight heparin beneath your skin each day. You or a family member learns to give these needles.</li> <li>Treatment of your blood clot goes on for your whole pregnancy and for at least 6 weeks after you have your baby.</li> <li>After you have your baby, your doctor might give you the same needle or switch you to a tablet. If you use the tablet you will have to travel for regular blood tests.</li> </ul>
<b>Risks &amp; Inconvenience</b>	<ul style="list-style-type: none"> <li>The needles sting. You bruise at the place where you put in the needle.</li> <li>You may get skin problems like itching or an itchy rash. If you get these problems, you may have to use a different type of heparin.</li> <li>Even though your doctor tells you that your baby is safe, you are worried that these blood thinning needles may not be safe for your baby.</li> <li>You doctor tells you that there may be a small increase in the risk of serious bleeding, thinning of the bones (osteoporosis) and having an allergic reaction to heparin called heparin-induced thrombocytopenia. If there is a risk, it is very small.</li> <li>Because you are using low molecular weight heparin, your doctor will need to make special plans for your delivery. If you go into labour when your blood is thinned, you may not be able to use the best way to reduce the pain of labour (a freezing needle in your back or epidural) and you may have a higher risk of bleeding. To prevent this, your delivery will be planned (also called an induction). If you go into labour early, your epidural may be delayed or you may not be able to receive one at all.</li> </ul>
<b>Long-term Consequences</b>	<ul style="list-style-type: none"> <li>There are no problems for your baby from the blood clot or from the low molecular weight heparin.</li> <li>Your leg goes back to normal. After needles or tables are stopped, you feel worried sometimes if you have pains in your leg.</li> <li>You have a higher risk of blood clots in the future (your risk may be 3 to 5% in the first year after you stop treatment; lower after that).</li> <li>Your doctor asks you if you would like to be tested for a clotting disorder.</li> <li>Your doctor tells you that you may have to take low molecular weight heparin needles if you get pregnant again.</li> </ul>

## Health state description for pulmonary embolism

<b>PREGNANCY-ASSOCIATED BLOOD CLOT IN THE LUNGS – PULMONARY EMBOLISM (PE)</b>	
<b>Symptoms &amp; Signs</b>	<ul style="list-style-type: none"> <li>For the past 3 days you find it hard to breathe while sitting. You have to rest if you climb stairs or walk outside of your home.</li> <li>You have pain in your chest when you take a breath.</li> <li>You feel very worried about your health and your baby.</li> </ul>
<b>Diagnosis &amp; Treatment</b>	<ul style="list-style-type: none"> <li>You have a test. When you have the test, you get a small dose of radiation. The radiation probably does not have any risk for you or your baby. If there is any risk, it is very small. The test tells your doctor that you have a blood clot in your lungs. You have to stay in hospital for several days.</li> <li>You worry about the effects this test and your blood clot might have on your baby.</li> <li>At first, your doctor treats you with blood thinners in your veins. After that you use needles of low molecular weight heparin. You take these needles beneath your skin every day for the rest of your pregnancy. You or a family member learns to give these needles.</li> <li>Treatment of your blood clot goes on for your whole pregnancy and for at least 6 weeks after you have your baby.</li> <li>After you have your baby, your doctor might give you the same needles or switch you to a tablet. If you take the tablet, you will have to travel for regular blood tests.</li> </ul>
<b>Risks &amp; Inconvenience</b>	<ul style="list-style-type: none"> <li>The needles sting. You bruise at the place where you put in the needle.</li> <li>You may get skin problems like itching or an itch rash. If you get these problems, you may have to use a different type of heparin.</li> <li>Even though your doctor tells you that your baby is safe, you are worried that these blood thinning needles may not be safe for your baby.</li> <li>Your doctor tells you that there may be a small increase in the risk of serious bleeding, thinning of the bones (osteoporosis), and having an allergic reaction to heparin called heparin-induced thrombocytopenia. If there is a risk, it is very small.</li> <li>Because you are using low molecular weight heparin, your doctor will need to make special plans for your delivery. If you go into labour when your blood is thinned, you may not be able to use the best way to reduce the pain of labour (a freezing needle in your back or epidural) and you may have a higher risk of bleeding. To prevent this, your delivery will be planned (also called an induction). If you go into labour early, your epidural may be delayed or you may not be able to receive one at all.</li> </ul>
<b>Long-term Consequences</b>	<ul style="list-style-type: none"> <li>There are no problems for your baby if it is not affected from the blood clot or from the low molecular weight heparin needles.</li> <li>Your breathing goes back to normal. After the needles or tablets are stopped, you feel worried sometimes if you have a pain in your chest or if you find it hard to breathe.</li> <li>You have a higher risk of blood clots in the future (your risk may be 3 to 5% in the first year after stopping treatment; lower after that).</li> <li>Your doctor asks you if you would like to be tested for a clotting disorder.</li> <li>Your doctor tells you that you may have to take low molecular weight heparin needles if you get pregnant again.</li> </ul>

## Health state description for major obstetrical bleed

MAJOR BLEED	
<b>Symptoms &amp; Signs</b>	<ul style="list-style-type: none"><li>You start to have pain in your abdomen, contractions and bleeding from your vagina in the later part of your pregnancy.</li></ul>
<b>Treatment</b>	<ul style="list-style-type: none"><li>You have to stay in the hospital.</li><li>Your doctor places a needle in your vein. You get fluids through this needle.</li><li>You stop taking your low molecular weight heparin.</li><li>You have more blood tests.</li><li>The doctor does an ultrasound to see how your baby is doing.</li><li>Your doctor does a test to see if your baby's heart is beating the way it should.</li><li>You stay in hospital for two or three days until your doctors are sure that your bleeding has slowed down or stopped.</li><li>Your doctor will see you frequently after you go home from the hospital.</li></ul>
<b>Recovery</b>	<ul style="list-style-type: none"><li>You are worried about your baby's health.</li><li>You may deliver early and may be more likely to need a caesarean section.</li></ul>
<b>Long-term Consequences</b>	<ul style="list-style-type: none"><li>Your baby is okay.</li><li>You feel worried with future pregnancies.</li><li>When you get pregnant again, your risk of similar bleeding problems is greater than if you had never had the bleeding problem.</li><li>In any future pregnancies, you will need to visit your doctor more often than if you had never had the bleeding problem.</li></ul>

**Appendix B. Decision quality scales****Decisional Conflict Scale**

	<b>Strongly disagree</b>	<b>Disagree</b>	<b>Neither agree nor disagree</b>	<b>Agree</b>	<b>Strongly agree</b>
1. I know which options are available to me	1	2	3	4	5
2. I know the benefits of each option	1	2	3	4	5
3. I know the risks and side effects of each option	1	2	3	4	5
4. I am clear about which benefits matter most to me	1	2	3	4	5
5. I am clear about which risks and side effects matter most	1	2	3	4	5
6. I am clear about which is more important to me (the benefits or the risks and side effects)	1	2	3	4	5
7. I have enough support from others to make a choice	1	2	3	4	5
8. I am choosing without pressure from others	1	2	3	4	5
9. I have enough advice to make a choice	1	2	3	4	5
10. I am clear about the best choice for me	1	2	3	4	5
11. I feel sure about what to choose	1	2	3	4	5
12. This decision is easy for me to make	1	2	3	4	5
13. I feel I have made an informed choice	1	2	3	4	5
14. My decision shows what is important to me	1	2	3	4	5
15. I expect to stick with my decision	1	2	3	4	5
16. I am satisfied with my decision	1	2	3	4	5

**Decision Satisfaction Scale**

	Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly agree
1. I was adequately informed about the different treatments available for my blood clot	1	2	3	4	5
2. The decision I made was the best decision possible for me personally	1	2	3	4	5
3. My decision was consistent with my personal values	1	2	3	4	5
4. I expect to successfully carry out (or continue to carry out) the decision I made	1	2	3	4	5
5. I had as much input as I wanted in the choice of treatment for my blood clot	1	2	3	4	5
6. I am satisfied with the decision that was made about treatment for my blood clot	1	2	3	4	5

## Decision Self-Efficacy Scale

### My confidence in making an informed choice

Below are listed some things involved in making an informed choice. Please show how confident you feel in doing these things by circling the number from 0 (not at all confident) to 4 (very confident) for each item listed below.

I feel **confident** that I can:

	<b>Not at all confident</b>	0	1	2	3	4	<b>Very confident</b>
1. Get the facts about the medication choices available to me	<b>Not at all confident</b>	0	1	2	3	4	<b>Very confident</b>
2. Get the facts about the benefits of each choice	<b>Not at all confident</b>	0	1	2	3	4	<b>Very confident</b>
3. Get the facts about the risks and side effects of each choice	<b>Not at all confident</b>	0	1	2	3	4	<b>Very confident</b>
4. Understand the information enough to be able to make a choice	<b>Not at all confident</b>	0	1	2	3	4	<b>Very confident</b>
5. Ask questions without feeling dumb	<b>Not at all confident</b>	0	1	2	3	4	<b>Very confident</b>
6. Express my concerns about each choice	<b>Not at all confident</b>	0	1	2	3	4	<b>Very confident</b>
7. Ask for advice	<b>Not at all confident</b>	0	1	2	3	4	<b>Very confident</b>
8. Figure out the choice that best suits me	<b>Not at all confident</b>	0	1	2	3	4	<b>Very confident</b>
9. Handle unwanted pressure from others in making my choice	<b>Not at all confident</b>	0	1	2	3	4	<b>Very confident</b>
10. Let the clinic team know what's best for me	<b>Not at all confident</b>	0	1	2	3	4	<b>Very confident</b>
11. Delay my decision if I feel I need more time	<b>Not at all confident</b>	0	1	2	3	4	<b>Very confident</b>

## Appendix C. Interview guide

### Interview data

Study ID	
Interview Date (day/month/year)	
Interview Location	
Interviewer	
Length of Interview (minutes)	
Treatment decision	
Decision analysis result	
Concordant or discordant?	

### Introduction

Hello, my name is (*name*) and I am the (*position such as research coordinator, research assistant*) on the [*name of study*]. The purpose of this interview is to learn about how you made the decision regarding whether or not to take heparin during your pregnancy. The interview today will last approximately 30 minutes.

We are most interested in learning about your personal experience with heparin and how you came to your treatment decision. There are no right or wrong answers.

Your participation is completely voluntary, and we can stop the interview at any time. The information from this interview will remain confidential and will not be shared with your care provider.

### Interview Questions

The questions in this interview are divided into four categories and will explore your experiences and perceptions as they relate to: 1) your decision-making process; 2) the direct choice exercise; 3) the personalized decision analysis; and 4) your knowledge about preventive treatment with heparin.

#### 1.0 Decision-Making Process

As part of this study you were asked to make a decision about taking heparin during your **current/future** pregnancy to prevent blood clots.

- 1.1 What is your preferred level of engagement when it comes to making a clinical decision? For example, do you prefer to have your health care provider make the treatment decision or do you do your own homework?

[If no reaction from the woman, we could provide an example (e.g. “for example, do you prefer to have your health care provider make the treatment decision or do you do your own homework and ask questions?”)]

- 1.2 Please describe to me the process you used to make your decision about heparin, which in your case was to **take/not take** heparin?
- 1.3 What types of information did you use to make your decision? [Try to discover previous knowledge/experience or personal research conducted on own]
  - a) Which information was most helpful in informing the decision you made?
  - b) Which information was the least helpful in informing the decision you made?

[If no reaction from the woman, we could provide an example (e.g. “for example, the decision aid had descriptions of relevant health outcomes” or “do you ask the doctor questions, review pamphlets, look up information online”)]

- 1.4 What factors do you think that influenced your final decision?
  - a) Are there any personal factors that influenced your decision? These can include your values, preferences, concerns, or previous experiences with treatment.
  - b) Are there factors related to your health care provider that influenced your decision?
  - c) Are there other factors prior to completing the direct choice or personalized decision analysis exercise today that influenced your decision?
- 1.5 What was the experience of being asked to make this decision like for you? [For all responses, follow up with a “why?” question]
  - a) At any point in time, did you experience feelings of confusion during the decision-making process? [if yes, have them describe when they experienced confusion]
  - b) What strategies did you use to address these feelings of confusion?
- 1.6 Once you made your final decision, how confident did you feel about the decision you made?
  - a) What factors increased your level of confidence and why?
- 1.6 Please explain to me how comfortable you are with the decision you made? Why?

## 2.0 Decision Using Direct Choice

As part of this study, you participated in a direct choice exercise in which you were presented with information about the risks and benefits of treatment along with different health outcomes.

- 2.1. Was the amount of information provided in the direct choice exercise appropriate? Why?
- 2.2. Did you have a clear understanding about the risks and benefits of heparin after completing the direct choice exercise?
  - a) Could you review the information and explain aloud the risks and benefits of treatment using actual numbers?
- 2.3. How did you weight the different aspects of information that were presented (e.g. the risks of experiencing another blood clot versus your personal preferences)?
  - a) Could you explain your rationale?

### 3.0 Decision Analysis Process

2.4. What ultimately drove your decision to **take/not** take low molecular weight heparin during your pregnancy?

2.5. What was the overall experience like for you in making a decision after the direct choice exercise?

Following the direct choice exercise, you received the results from your personalized decision analysis. Decision analysis involves asking you about your preferences for health outcomes related to the treatment decision. Using a mathematical formula, we then combine this information with the risk probability of each health outcome to formulate a treatment recommendation. This recommendation is based on a score that takes into account the likelihood of each health outcome occurring and the importance you assigned to them. It indicates whether a treatment is likely to lead to an increase or decrease in your quality of life.

3.1a Please describe your experience with the rating scale, feeling thermometer and gamble exercises that we completed.

3.1b Did these exercises help clarify your personal preferences for the different health outcomes (e.g. experiencing a blood clot)?

3.1c Do you think these exercises reflected your personal preferences?

3.2 What were your thoughts and reactions when you were told the results from the personalized decision analysis process?

**CONCORDANT DECISIONS** [The research assistant would get the information on concordant and discordant decisions from the table at the beginning of the interview guide]

3.3a For you, there was consistency between the decision you made after the direct choice exercise and the results from the decision analysis process.

After reviewing treatment information, YOU made the decision to **take/not** **take** heparin. The result of the decision analysis also supported this decision to **take/not take** heparin

How did this consistency make you feel? Why?

**DISCORDANT DECISIONS:** [as above, the research assistant will explain the discordance to set the context]

3.3b For you, there was a difference between the decision you made after the direct choice exercise and the results from the decision analysis process.

After reviewing treatment information, YOU made the decision to **take/not** **take** heparin while the result of the personalized decision analysis recommended that you **take/not take** heparin. We would like to insist on the fact that there is no right or wrong decision in this context.

Having said this, the discordant decision could reflect a difference between the methods we used to formulate a treatment recommendation with the mathematical formula and the factors you considered as a patient.

Our objective is to identify the cause of this difference. We would like to start by ask how did this inconsistency make you feel? Why?

**If the participant modified her initial decision:**

- 3.4a Please explain why you changed your decision after receiving the results from the decision analysis?
- 3.4b How do you think the results from the decision analysis influenced your levels of confidence or comfort with your final decision?
- 3.4c Did you find having the results of the decision analysis useful for making your decision?
- 3.4d Would you find having the results of a decision analysis useful for making other difficult health care decisions?
- 3.4e Would you have preferred to have only gone through the personalized decision analysis exercise instead of making the decision yourself first with the decision aid? In other words, would you rely on the personalized decision analysis exercise rather than making the decision by yourself?

**If the participant did not modify her initial decision:**

- 3.4f Please explain why you maintained your decision after receiving the results from the personalized decision analysis?
- 3.4g How do you think the results from the personalized decision analysis influenced your levels of confidence or comfort with your final decision?
- 3.4dh Did you find having the results of the decision analysis useful for making your decision?
- 3.4i Would you find having the results of a personalized decision analysis useful for making other difficult health care decisions?
- 3.4j Would you have preferred to have only gone through the decision analysis exercise instead of making the personalized decision yourself first with the decision aid? In other words, would you rely on the personalized decision analysis exercise rather than making the decision by yourself?

#### **4.0 Treatment Knowledge**

To finish, we have some quick questions regarding your knowledge of heparin. Throughout this study, you have been provided with information about the use of heparin to potentially reduce the risk of blood clots during pregnancy.

- 4.1 From your perspective, what are the benefits of treatment, which involves daily injections of heparin throughout pregnancy, to prevent blood clots?
- 4.2 From your perspective, what are the potential drawbacks related to daily injections of heparin throughout pregnancy?

4.3 Is there any additional information that you would like to share about the process of making a decision about treatment for blood clots?